Most Breast Implant–Associated Lymphomas Have Indolent Clinical Course
A case series of rare peripheral T-cell lymphoma that is associated with breast implants found that most cases have an indolent clinical course.
Noninferiority of Neoadjuvant Chemo Cannot Be Confirmed in Ovarian Cancer Trial
The noninferiority of neoadjuvant chemotherapy vs upfront surgery could not be confirmed with regard to overall survival in patients with ovarian, tubal, and peritoneal cancers.
Olaparib Plus Vistusertib Promising in Early Trial of Endometrial, Other Cancers
The combination of the PARP inhibitor olaparib with the mTORC1/2 inhibitor vistusertib had promising activity across endometrial, ovarian, and triple-negative breast cancers.
Nivolumab More Effective Than Ipilimumab in Resected High-Risk Melanoma
Extended follow-up from the CheckMate 238 trial confirmed the superior efficacy of nivolumab vs ipilimumab in patients with stage III and IV resected melanoma.
Adding Abemaciclib Offers Good Outcomes in Pre-/Perimenopausal Breast Cancer
The addition of abemaciclib to fulvestrant significantly improved PFS and time to subsequent chemotherapy in pre- and perimenopausal HR-positive/HER2-negative breast cancer patients.
Ribociclib Plus Fulvestrant Offers Improved PFS in Advanced Breast Cancer
The combination of ribociclib and fulvestrant yielded an improvement in progression-free survival in postmenopausal women with advanced breast cancer, according to the MONALEESA-3 trial.
Acquired Mutations in Breast Cancer Can Explain Resistance to Palbociclib/Fulvestrant
Several different driver mutations acquired during treatment for breast cancer can help explain acquired resistance to the combination of palbociclib and fulvestrant.
Adding Ribociclib Improves PFS in Premenopausal Breast Cancer
Ribociclib plus endocrine therapy resulted in improved PFS in premenopausal women with HR+, HER2− advanced breast cancer.
MEK/BRAF Inhibition May Overcome Molecular Heterogeneity of BRAF-Mutant Melanoma
Deeper inhibition of the MAPK pathway by targeting both MEK and BRAF may help improve progression-free survival outcomes in patients with advanced BRAF V600–mutated melanoma.
Secondary Surgery Associated With Improved Survival in Ovarian Cancer
A secondary cytoreductive surgery along with chemotherapy following recurrence in patients with epithelial ovarian cancer offered improved outcomes over treatment with chemotherapy alone.
Cell-Free DNA Assay Can Help Monitor Melanoma for Metastasis
The presence and burden of single nucleotide variants as measured in cell-free DNA may have substantial prognostic utility in patients with melanoma who have metastases.
“Screening Pill” Could Offer Noninvasive Breast Cancer Screening Method
Researchers have developed a “disease screening pill” that could allow for a noninvasive and safe method for detecting breast cancer using only near-infrared light.
Trabectedin Plus PLD Shows Benefit in Real-Life Ovarian Cancer Setting
Trabectedin plus pegylated liposomal doxorubicin offered clinical benefit in a real-life setting of patients with previously treated platinum-sensitive recurrent ovarian cancer.
Targeting AXL Could Slow Metastasis in HER2-Positive Breast Cancer
New research has found that expression of AXL is correlated with poor outcomes in patients with HER2-positive breast cancer.
Single Gemcitabine Instillation Can Reduce Urothelial Cancer Recurrence
An intravesical instillation of gemcitabine following TURBT reduced the risk of recurrence in patients with suspected low-grade non–muscle-invasive urothelial cancer.
Dose-Dense Chemo Shows Promise as Neoadjuvant Therapy in Bladder Cancer
A neoadjuvant dose-dense regimen was active and well tolerated in patients with muscle-invasive bladder cancer, allowing downstaging of most patients before radical cystectomy.
USPSTF Recommends That PSA Screening Be an Individual Decision
The US Preventive Services Task Force issued a final recommendation on prostate cancer screening, including that men aged 55 to 69 years should make an individual decision on whether or not to be screened.
Osimertinib Improves Patient-Reported Outcomes in Advanced NSCLC
An analysis of patient-reported outcomes showed that osimertinib yielded a longer time to deterioration compared with chemotherapy in patients with advanced non–small-cell lung cancer.
Dabrafenib/Trametinib Combination Approved in BRAF-Mutant Melanoma
The FDA granted approval to the combination of dabrafenib and trametinib for the adjuvant treatment of melanoma, specifically in patients with a BRAF V600E or V600K mutation.
Lab Study Shows HER2 Inhibitor Lapatinib Can Induce Cell Proliferation
A laboratory study has found that the HER2 inhibitor lapatinib used to slow HER2-positive breast cancer can actually induce tumor growth in some circumstances.
Online Tool for Reporting Prostate Cancer Comorbidities Shows Promise
An at-home online survey was found to be a reasonably accurate way to collect patient comorbidities prior to a physician visit in patients with prostate cancer.
New Model Can Assess Breast Cancer Risk in Women With Atypical Hyperplasia
Researchers have developed a new model to help predict the development of breast cancer in women with atypical hyperplasia based on a breast biopsy.
Alectinib Improves PFS, CNS Responses in Crizotinib-Treated ALK+ NSCLC
Alectinib offered significantly improved outcomes over standard chemotherapy in patients with ALK-positive non–small-cell lung cancer who had progressed on crizotinib therapy.
Married Melanoma Patients Present at an Earlier Stage
Melanoma patients who are married tend to present at earlier stages of the disease than those who are not married, divorced, or widowed; marital status was also associated with the likelihood of undergoing SLNB.
Whole-Genome Analyses Expand Genetic Picture of Prostate Cancer
A study found some mutations that are already targeted by approved or investigational drugs for prostate cancer, along with dozens of targets that should be considered as candidates for future trials.
Neoadjuvant Nivolumab Yields High Response in Newly Diagnosed NSCLC
Neoadjuvant nivolumab combo proved safe while yielding high response rates in patients with NSCLC.
Pembrolizumab Plus Chemo Improved Survival in Advanced NSCLC
In KEYNOTE-189, a pembrolizumab/chemo combination yielded OS and PFS benefits in patients with advanced NSCLC.
Prognostic Tool Can Guide Extended Endocrine Therapy in ER+ Breast Cancer
A simple prognostic tool could be used to identify patients with HR-positive breast cancer who underwent 5 years of endocrine treatment and who might be at higher risk of late distant recurrence.
TLR9 Agonist May Reverse Resistance to Immune Checkpoint Inhibition in Melanoma
Treatment with the TLR9 agonist CMP-001 appeared to potentially reverse resistance to immune checkpoint inhibition in patients with metastatic melanoma.
Promising Personalized Ovarian Cancer Vaccine Induces Immune Responses
A personalized cancer vaccine was well tolerated and was capable of inducing antitumor T-cell immunity in patients with recurrent ovarian cancer.